Personalized medicine in the adjuvant chemotherapy of stage II colon cancer--are we there yet?

Over the past few years, significant efforts have focused on developing and validating molecular biomarkers to better define the subset of patients with stage II disease who might derive benefit from adjuvant therapy.

[1]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[2]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Kerr,et al.  A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Cubiella,et al.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer , 2005, Gut.

[5]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[6]  S. Paik,et al.  Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). , 2012 .

[7]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gafà,et al.  Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.

[10]  D. Sargent,et al.  Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. , 2006, Gastroenterology.

[11]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Leppert,et al.  Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  A. Goel,et al.  Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines , 2003, International journal of cancer.

[15]  M. Brouwers,et al.  Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[18]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[19]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Schilsky,et al.  Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Schilsky,et al.  Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Hurwitz,et al.  Use of molecular biomarkers to inform adjuvant therapy for colon cancer. , 2013, Oncology.